Skip to content
Search

Latest Stories

GPhC register witnesses 2.5% increase of pharmacists registered in last one year

The General Pharmaceutical Council (GPhC) has witnessed a 2.5 per cent increase of pharmacists on register in the last one year. 

According to GPhC registers data, there has been a rise of pharmacists by 1,518 from 61,139 on 31 May 2022 to 62,657 on 31 May 2023. 


Of the 62,657 pharmacists, 1,742 (2.8 per cent) have a registered address outside of Great Britain. These include recent joiners who have yet to register an address in Great Britain. Others have left Great Britain and are overseas but would like to retain their GPhC registration or have yet to leave the register. 

When compared monthly, till 31 May 2023, the total number of pharmacy professionals on the register increased by 98 to 88,176 from 88,078 at the end of April 2023 -- 71 per cent pharmacists (62,681) and 29 per cent pharmacy technicians (25,495).

However, when split by profession type, it was noted that there has been an overall decrease of five pharmacists and an increase of 50 pharmacy technicians from April 2023. 

The number of pharmacists with a prescribing annotation has increased by 240 from 15,790 on 30 April 2023 to 16,030 on 31 May 2023. This now represents 25.6% of registered pharmacists where the overall proportion is continuing to increase.

There were 13,709 registered pharmacies on 31 May 2023, a decrease of 97 from last month in total (93 less in England, one less in Scotland and three less in Wales). 

The Council said in its report: “The overall numbers of pharmacies have been falling in the last eight years in England and Wales with some increases in Scotland, where numbers fluctuate monthly.” 

As on 31 May 2023, the number of registered pharmacists having a prescriber annotation has increased by 240 since the last month to 16,030 out of 62,657, this is 25.6% of the register. 

These include 14,871 independent prescribers only, 915 pharmacists who hold both independent and supplementary prescribing annotations and 244 supplementary prescribers only.  

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less